Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00460057
Status:
COMPLETED
Last Update Posted:
2014-08-05
First Post:
2007-04-12
Brief Title:
The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss
Sponsor:
Eulji University Hospital
Organization:
Eulji University Hospital
Study Overview
Official Title:
The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
High bone turnover with the bone resorption exceeding bone formation is a major mechanism of postmenopausal osteoporosis Therefore inhibition of bone resorption is a rational approach for the prevention The Objective of the current study was to determine the short-term efficacy of once-weekly low dose alendronate in the prevention of bone loss in early postmenopausal Korean women with moderate bone loss via bone turnover markers
This study was a 12-week randomized double-blind clinical trial compared the effects of placebo with alendronate 20 mg once weekly All subjects received supplemental calcium 600 mg and vitamin D 400 IU daily Fifty two postmenopausal women the ages between 50-65 year with lumbar spine BMD at least 20 SD below the peak young adult mean were recruited at Eulji University Hospital Daejeon Korea BMD was measured by DXA at baseline and serum alkaline phosphatase osteocalcin and C-terminal telopeptide of type I collagen was measured at baseline and 12 weeks after treatment
This study was a 12-week randomized double-blind clinical trial compared the effects of placebo with alendronate 20 mg once weekly All subjects received supplemental calcium 600 mg and vitamin D 400 IU daily Fifty two postmenopausal women the ages between 50-65 year with lumbar spine BMD at least 20 SD below the peak young adult mean were recruited at Eulji University Hospital Daejeon Korea BMD was measured by DXA at baseline and serum alkaline phosphatase osteocalcin and C-terminal telopeptide of type I collagen was measured at baseline and 12 weeks after treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None